Latest News

A JAMA Dermatology study found expert dermatologists achieved the highest multiclass diagnostic accuracy when tested against AI across a realistic spectrum of skin lesions.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Do patients really need to stop using retinoids in the summer or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Dermatologists and oncologists at a Dermatology Times Evolving Paradigms event in Dallas compared immunotherapy selection, adverse event management, and referral practices in advanced cutaneous squamous cell carcinoma.

Placebo-arm RCTs show gentle cleansing, moisturizing, and sunscreen alone can significantly improve acne, rosacea, AKs, melasma, and PIH, boosting outcomes beyond prescriptions.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

New phase 3 data presented at the AAD Innovation Academy show zasocitinib achieved high rates of clear or almost clear skin at the scalp, palms, soles, and nails at week 16.

Anatomy-guided VectorLift thread lift cuts pain and downtime, lowers bruising risk, and delivers comparable facial lifting in real-world patient study.

New phase 3 data show oral TYK2 inhibitor soficitinib improves moderate-to-severe atopic dermatitis, easing itch with no new safety signals.

This review of the latest dermatological studies includes insights on gut dysbiosis in inflammatory conditions, air pollution and vitiligo risk, emollient use in AD patients, and more.

New JCI research identifies succinate/SUCNR1 signaling as a potential mechanistic link between hyperglycemia and worsening vitiligo.

Low vitamin B12 levels link to longer-lasting wheals and heavier symptom burden in chronic spontaneous urticaria, suggesting a simple lab check for stubborn cases.

Clinicians at a Dermatology Times Case-Based Roundtable event worked through 3 vitiligo cases spanning new-onset, widespread, and pediatric disease, weighing treatment sequencing against real-world access barriers.